{"product_id":"nabota-200units","title":"Nabota 200","description":"\u003ch2\u003eNabota: Botulinum Toxin Type A by Daewoong\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eNabota\u003c\/strong\u003e is a botulinum toxin type A product developed by Daewoong Pharmaceutical in South Korea. Understanding its clinical evidence and its relationship to other toxin brands can help inform a discussion with a qualified healthcare professional. This listing is for \u003cstrong\u003eNabota 200U\u003c\/strong\u003e, containing 200 units per vial, one of the presentations in Daewoong's Nabota range.\u003c\/p\u003e\n\n\u003ch2\u003eKey Features and Benefits of Nabota\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTargeted Frown-Line Improvement:\u003c\/strong\u003e Helps soften the appearance of glabellar expression lines by reducing activity in the muscles involved in frowning.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEarly Visible Response:\u003c\/strong\u003e A clinical study observed improvement in most evaluated participants by day two, although individual response times vary.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical Evidence:\u003c\/strong\u003e Published studies assess early response and comparative efficacy for glabellar lines. Explore the findings and study details below.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDeveloped by Daewoong:\u003c\/strong\u003e A South Korean botulinum toxin type A product from Daewoong Pharmaceutical.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eHow Nabota Works on Expression Lines\u003c\/h2\u003e\n\u003cp\u003eBotulinum toxin type A inhibits the release of acetylcholine, a chemical messenger involved in muscle contraction. Reducing activity in the targeted muscles can soften the expression lines associated with that movement. The Nabota research discussed below focuses on glabellar lines: the frown lines between the eyebrows.\u003c\/p\u003e\n\n\u003ch2\u003eClinical Evidence Behind Nabota\u003c\/h2\u003e\n\u003ch3\u003eWhat the Onset Study Found\u003c\/h3\u003e\n\u003cp\u003eA 2018 phase 4 study enrolled 42 adults and evaluated changes in glabellar lines over 14 days. Among 41 participants included in the efficacy analysis, 85.4% showed at least a one-point improvement at maximum frown on day two. This small, open-label study had no comparison group and was sponsored by Daewoong. It describes early response, not a guaranteed onset time or long-term duration. \u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6177673\/\"\u003eRead the Nabota onset study\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch3\u003eWhat the Botox Comparison Studied\u003c\/h3\u003e\n\u003cp\u003eA randomized, double-blind phase 3 trial enrolled 540 adults with moderate to severe glabellar lines and compared prabotulinumtoxinA, onabotulinumtoxinA, and placebo. The researchers concluded that prabotulinumtoxinA met the study's non-inferiority criterion against onabotulinumtoxinA. That finding supports efficacy within the trial's defined conditions; it does not establish that one brand is better for every patient or treatment area. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30951166\/\"\u003eRead the comparative clinical trial\u003c\/a\u003e.\u003c\/p\u003e\n\u003cp\u003eThese studies provide context for the product family. They do not compare 100U and 200U vial sizes or demonstrate that a larger vial produces stronger or longer-lasting results.\u003c\/p\u003e\n\n\u003ch2\u003eNabota vs Botox: Understanding the Comparison\u003c\/h2\u003e\n\u003cp\u003eNabota and Botox are separate brands of botulinum toxin type A. Sharing a toxin type does not make them the same finished product. When assessing a comparison, consider the specific treatment area, how improvement was measured, and when the researchers assessed it.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical findings:\u003c\/strong\u003e A result for glabellar lines should not be treated as proof of equivalent outcomes across all facial areas.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct selection:\u003c\/strong\u003e A clinician should use the prescribing information for the actual product rather than relying on a brand comparison alone.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eUnits:\u003c\/strong\u003e Botulinum toxin potency units are product-specific. For example, the Jeuveau prescribing information explicitly states that its units cannot be converted into those of other botulinum toxin products. A clinical comparison is not a dose-conversion guide. \u003ca href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=17a914c1-e54b-4b50-965d-b0fd9111bba4\"\u003eSee the Jeuveau prescribing information\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNabota Product Information\u003c\/h2\u003e\n\u003cp\u003eThis product contains \u003cstrong\u003e200 units per vial\u003c\/strong\u003e and is manufactured by Daewoong Pharmaceutical. The vial content identifies the product presentation, not the amount an individual should receive. Administration requires a qualified healthcare professional following the applicable product instructions.\u003c\/p\u003e\n\u003cp\u003eBefore use, review the supplied labeling, expiry date, and storage instructions. Suitability, treatment planning, and follow-up should be discussed with the treating clinician.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eDoes an early response mean the full result is already visible?\u003c\/h3\u003e\n\u003cp\u003eNo. The onset study measured improvement at several visits, and early improvement was distinct from later assessments. A day-two response should not be interpreted as the final result for every patient.\u003c\/p\u003e\n\u003ch3\u003eIs the FDA approval for Jeuveau also an approval for this Nabota vial?\u003c\/h3\u003e\n\u003cp\u003eNo. The FDA record identifies Jeuveau, approved in 2019. It does not establish FDA approval for the Nabota-branded 200U product listed here. Product names, presentations, and approved uses must be checked for the country of use. \u003ca href=\"https:\/\/purplebooksearch.fda.gov\/index.cfm?blaNo=761085\u0026amp;event=productdetails\"\u003eView the FDA's Jeuveau record\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch3\u003eWhat should I discuss with my clinician before treatment?\u003c\/h3\u003e\n\u003cp\u003eDiscuss your goals, medical history, medicines, previous botulinum toxin treatments, and any prior reactions. Ask about the expected benefit, possible side effects, and follow-up for the specific product being considered.\u003c\/p\u003e\n","brand":"Celmade","offers":[{"title":"Default Title","offer_id":43372185682145,"sku":"BT1018","price":90.2,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0666\/6761\/0337\/files\/Nabota_200.png?v=1765689718","url":"https:\/\/cilmade.com\/products\/nabota-200units","provider":"Celmade","version":"1.0","type":"link"}